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Vector control is the only widely utilised method for primary prevention and control of den-
gue. The use of pyriproxyfen may be promising, and autodissemination approach may
reach hard to reach breeding places. It offers a unique mode of action (juvenile hormone
mimic) and as an additional tool for the management of insecticide resistance among Aedes
vectors. However, evidence of efficacy and community effectiveness (CE) remains limited.
Objective
The aim of this systematic review is to compile and analyse the existing literature for evi-
dence on the CE of pyriproxyfen as a vector control method for reducing Ae. aegypti and
Ae. albopictus populations and thereby human dengue transmission.
Methods
Systematic search of PubMed, Embase, Lilacs, Cochrane library, WHOLIS, Web of Sci-
ence, Google Scholar as well as reference lists of all identified studies. Removal of dupli-
cates, screening of abstracts and assessment for eligibility of the remaining studies
followed. Relevant data were extracted, and a quality assessment conducted. Results were
classified into four main categories of how pyriproxyfen was applied: - 1) container treat-
ment, 2) fumigation, 3) auto-dissemination or 4) combination treatments,–and analysed with
a view to their public health implication.
Results
Out of 745 studies 17 studies were identified that fulfilled all eligibility criteria. The results
show that pyriproxyfen can be effective in reducing the numbers of Aedes spp. immatures
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with different methods of application when targeting their main breeding sites. However, the
combination of pyriproxyfen with a second product increases efficacy and/or persistence of
the intervention and may also slow down the development of insecticide resistance. Open
questions concern concentration and frequency of application in the various treatments. Area-
wide ultra-low volume treatment with pyriproxyfen currently lacks evidence and cannot be rec-
ommended. Community participation and acceptance has not consistently been successful
and needs to be further assessed. While all studies measured entomological endpoints, only
two studies measured the reduction in human dengue cases, with inconclusive results.
Conclusions
Although pyriproxyfen is highly effective in controlling the immature stages of dengue trans-
mitting mosquitoes, and–to a smaller degree–adult mosquitoes, there is weak evidence for
a reduction of human dengue cases. More well designed larger studies with appropriate
standardised outcome measures are needed before pyriproxyfen is incorporated in routine
vector control programmes. Additionally, resistance to pyriproxyfen has been reported and
needs investigation.
Author summary
There is evidence that pyriproxyfen may effectively reduce the density of immature mos-
quito stages when applied to identified breeding sites. Various formulations are commer-
cially available, and easy to use without a health threat to the user. However, questions
remain regarding its use as a single agent in a community setting. Considering its mode of
action, it would not be the product of choice for use in an acute outbreak setting. How-
ever, for a sustainable community approach, especially slow-release pyriproxyfen formula-
tions seem promising, because they are the longest lasting choice. The analysis suggests,
that combination with a second vector control chemical, preferably an adulticide tackling
different stages of mosquito development, increases the efficacy of pyriproxyfen and pro-
longs the duration of a single application. This systematic literature review clearly shows
that there is a need for further studies, preferably utilising cluster-randomised controlled
(cRCT) designs, to investigate the community effectiveness of pyriproxyfen and to link
entomological outcomes to human dengue transmission.
Introduction
Over the past five decades, the global burden of dengue is estimated to have increased massively:
Bhatt et al. [1] postulated that in 2010 there were 96 million apparent, and 294 million unappar-
ent infections worldwide, with 22,000 registered dengue-related deaths reported in 2014 [2].
Transmission of dengue is through infective bites of female Aedes aegypti (L.) (Diptera: Culi-
cidae) mosquitoes and, to a lesser extent, of Ae. albopictus (Skuse). The immature stages of the
Aedes mosquitoes are found in water filled containers [3].
In the absence of anti-viral medication and with the first commercially available vaccine
not yet widely available for public health use [4], vector control remains the cornerstone for
dengue prevention [5,6]. Due to their behaviour, adult mosquitoes transmitting dengue are
difficult to attack and larviciding as well as larval source reduction are often the first choice of
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intervention. Larvicides have most often been implemented against Ae. aegypti as it breeds
almost exclusively in domestic water containers. Ae. albopictus uses both, artificial and natural
breeding sites [7] and is therefore more difficult to tackle.
Pyriproxyfen is an insect growth regulator (IGR) with a slow-acting larvicidal activity
against a broad spectrum of public health insect pests [8] and it is being used extensively
worldwide both in public and private settings. Acting on the endocrine system of insects by
mimicking the juvenile hormone, pyriproxyfen hinders molting and subsequently inhibits
reproduction. In addition, it causes morphological and functional aberrations in emerging
adults, such as decreased fecundity and fertility. Due to its very low mammalian toxicity [9],
pyriproxyfen is approved by the World Health Organization (WHO) for the treatment of pota-
ble water against mosquitoes [10].
Pyriproxyfen has been studied extensively in experimental, i.e. controlled laboratory or
semi-field settings, with evidence of efficacy against immature Aedes spp. [11,12]. Yet, in field
application studies, pyriproxyfen demonstrated mixed outcomes regarding its effectiveness as
well as persistence. To date, no systematic review of the scientific literature has been under-
taken to examine the evidence for the effectiveness of pyriproxyfen against dengue vectors.
Therefore, the objective of this study is to review systematically the available literature for evi-
dence on the community effectiveness (CE) of pyriproxyfen as a vector control method reduc-
ing Ae. aegypti and Ae. albopictus populations and dengue transmission.
Methods
This review follows the reporting guidelines set forth in the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) Statement for systematic reviews and meta-
analyses [13] (Fig 1).
Inclusion and exclusion criteria
The following inclusion criteria were used: 1) Studies providing original research dealing with
the CE of pyriproxyfen—alone or in combination with other chemical vector control products.
2) As for study types, included were any cRCTs or randomised controlled trials (RCT); non-
RCTs (nRCT) only if they were relevant to the research question and using a control, e.g.
quasi-randomised controlled trials (quasi-RCTs), intervention control trials, controlled before
and after studies. Unlike in RCTs, allocation in quasi-RCTs is performed in a way that is open
to systematic bias, i.e. chances of being in one group or another are not equal. In cRCTs, pre-
existing groups of participants are allocated to (or against) an intervention. Intervention con-
trol studies use methods designed to examine efficacy or effectiveness of an intervention in a
group but do not use randomisation. 3) Any study that applied pyriproxyfen in the field—
defined as any community or environment where dengue vectors naturally occur—was con-
sidered CE and included in the analyses.
Efficacy studies, defined as trials performed under laboratory conditions were excluded. Of
the studies that undertook both methods, only the CE component was considered. Inclusion
criteria included the above-mentioned study types, to give a broader picture of existing studies,
since vector-control studies have varying designs and information may be useful.
Search strategy
Two researchers independently carried out the literature search until 01 August 2016 with no
starting time limit. The search was conducted in English, but articles were not excluded if the
full text was not available in English. The search strategy was applied to the following seven
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databases to locate peer-reviewed studies: PubMed, Web of Science, EMBASE, LILACS,
WHOLIS and Cochrane. In addition, grey literature using Google Scholar has been searched.
Search terms were divided into three broad categories, including 1) disease relevant terms,
2) vector relevant terms and 3) intervention relevant terms. For the disease category, the terms
Fig 1. PRISMA flowchart of the selection process.
https://doi.org/10.1371/journal.pntd.0005651.g001
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were: Dengue, Dengue haemorrhagic fever, Dengue shock syndrome, along with the abbrevia-
tions DF (dengue fever), DHF (dengue haemorrhagic fever), DS (dengue syndrome), and DSS
(dengue shock syndrome); for the vector category: Aedes, Aedes aegypti, Aedes albopictus; and
for the intervention category: pyriproxifen, and insect growth regulator.
Once screened for duplicates by author, title, journal and publication date, eligible studies
were screened against the inclusion criteria. At first, titles and abstracts were screened by two
independent reviewers, in a second step articles were reviewed in full and relevant information
was extracted into the evidence table (Table 1). A third reviewer was available for the potential
case of disagreement between the two independent reviewers. Studies were assessed for quality
using the assessment of multiple system reviews (AMSTAR) [14]. For the purpose of this
review, the overall quality of studies was not used to exclude studies, but as a tool for evaluating
the impact of the reported outcomes.
A comparative analysis of the main study outcomes was conducted, using the quality of
each individual study as a weighing tool. The use of randomisation, the calculation of sample
sizes and the size of the unit of allocation all impacted the weight individual studies were
assigned. Finally, analytical categories were developed based on the method of pyriproxyfen
application. These categories were: 1) container treatment, 2) fumigation, 3) auto-dissemina-
tion, and 4) combination of pyriproxyfen with adulticides. As for 1), ‘container treatment’ is
for the purpose of this review defined as any intervention performed by using any kind of
Aedes spp. infested containers (Table 2).
Results
745 articles were identified from the different databases for assessment (Fig 1). After removing
duplicates (n = 698), 47 were left for closer analysis. An additional two studies were identified
from the reference lists of the above. Applying full inclusion and exclusion criteria on these 49
studies, 17 met the pre-specified eligibility criteria. Eight of the studies were classified as CE
studies, while nine reported both efficacy as well as CE components.
Common reasons for the exclusion of potentially relevant studies included the following: 26
studies reported only efficacy; one study was a meta-analysis without original data [15]; and
for one study [16] the pyriproxyfen component of the intervention was not accepted by the
community and therefore not analysed. Another CE study [17] had multiple study arms, but
the arm in which pyriproxyfen was tested against Aedes was a simple intervention design with-
out a control and was therefore excluded. Similarly, another study [18] described the use of
pyriproxyfen against Aedes only as a simple intervention and did not use it in its RCT part.
One proved to be a simple intervention [19] and one combined efficacy and CE study [20] was
excluded as it did not use pyriproxyfen in its CE part.
General study characteristics
The included studies were published between 2005 and 2014 (Table 1). One was in Thai the
others in English. Seven of the studies were conducted in Central or South America (four in
Argentina [21,22,23,24], one in Colombia [25], two in Peru [26,27]; four in Southeast Asia
(one in Cambodia [28], two in Thailand [29,30], one in Vietnam [31]); two in the USA [32,
33], two in Martinique [34,35], and two in Europe (Italy [36], Netherlands [38]).
Information on potential confounding factors such as the socio-economic status of resi-
dents [23,25,28,31,33] or housing construction [22,28] was not systematically reported.
Weather conditions, either historical or during the intervention period, were reported in six of
the studies [26,28,31,32,33,35]. No study incorporated a specific economic analysis or provided
cost estimates for consideration.
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The most common study design was nRCT, used in 12 studies. Three were RCTs, one
quasi-RCT and one cRCT. Regarding the vectors, Ae. albopictus alone was studied in two of
the included studies [33,36], one study [32] tackled both, Ae. aegypti and Ae. albopictus, both
laboratory-reared. The remaining 14 studies looked at Ae. aegypti only.
Study objectives and interventions. While all included studies had a CE element, some
also examined the efficacy of pyriproxyfen [25,27], or resistance [35]. Others looked at differ-
ent application forms, including auto dissemination [26,27,33,36,37], fumigation [22], ULV
application [21,32], long-lasting materials [24,31], and controlled-release application [28,31].
Some tested the combination of pyriproxyfen with another active ingredient; seven of the eight
CE studies used it either in combination with another product—permethrin [22,23,31], Beau-
veria bassiana [37]—or compared it to other products [21,29].
Among the studies with both CE and efficacy arms, three used pyriproxifen either in com-
bination with spinosad [34] or temephos [29] or compared its effects with other vector control
methods (temephos, diflubenzuron, Bti, spinosad; [35]).
Sample sizes and units of allocation. Various methods of pyriproxyfen application were
used and information on sampling and reporting of sample size was often limited, making
comparisons between the studies difficult. The largest study included communities with a total
of 97,262 people [25], followed by 64,591 people [21]. Both studies were conducted in urban
settings, facilitating a high coverage. Tsunoda [31] performed their intervention in a town of
12,000 inhabitants, while Marcombe [35] and Darriet [34] chose smaller settings, described as
‘three separate villages’, though the exact size population-wise is not specified. Two studies
[27,30] were conducted in rural areas and reported a sample size of two villages (65/71 houses
with 160/171 inhabitants) and 16 households, respectively. Likewise, [29] was undertaken in
four villages in Thailand.
The included studies also differed regarding the scale of the intervention; and, again, the
reporting of this information varied widely. Sizes and makings of containers were most com-
monly reported as units of allocation. Others treated defined surface areas with different formula-
tions and concentrations of pyriproxyfen. Some had more than one unit of allocation depending
on method and study design. The smallest intervention was a cage with 50 free-flying Aedes mos-
quitoes [37], followed by [24] with 3 x 200 liter tanks and [34] with 15 containers of various sizes.
The largest intervention [25] comprised the catch basins of a whole town (32.224 houses).
The follow up-periods—defined as the total intervention period from the first intervention
day to the last day at which the endpoints were measured and reported—varied greatly. They
ranged from 12 days [36] to nine months [35] with a median follow-up time of five months.
Table 2. Table of categories. Note that these categories are not mutually exclusive. Some studies are
included in more than one category.
Category Description
Container Treatment For the purpose of this review, defined as any intervention performed on
any kind of Aedes spp. infested containers
Fumigation Fumigant canisters are thermal active systems generating smoke; they
have been shown to work against Ae. aegypti, (Masuh et al. 2003)
Auto-dissemination In auto-dissemination, the insecticide is dispersed by the insects
themselves. Adult Aedes topically contaminated with pyriproxyfen can
transfer enough material to untreated water containers to exert a
significant lethal effect on immature stages developing therein
Combination of pyriproxyfen
with adulticides
Combining products with different ways of action can increase the
intensity or the effect of an intervention. A precondition is that the
combined products do not inhibit each other
https://doi.org/10.1371/journal.pntd.0005651.t002
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Outcome measures. The reported outcome measures differed depending on the respec-
tive research question and intervention (Table 3). The most widely used outcome measure,
reported by 11 of the 17 studies, was per cent adult emergence inhibition (EI) [21,22,23,24,26,
28,32,33,34,35,37].
Regarding entomological indices, three studies reported Breteau Index (BI) only [21,22,25]
and one BI and Container Index (CI) [23]. Pupae per person (PPP), currently considered the
most highly associated with the density of adult vectors (36), was only reported by one study
[23]. Pupal mortality [25,26,27,29,33,36], larval mortality [25,26,27,29,37], Relative Density
[35], adult indices [22], and Container Index [31] were also used.
Only two studies linked human transmission data. One study [31] used serological surveys
(Immunoglobulin M), Ocampo [25] measured dengue case incidence, drawn from the
national reporting system.
Analysis of container treatment studies
Ten studies [21,23,24,25,27,28,32,33,34,35] assessed the feasibility and efficacy of container
treatment. Two studies were RCTs [25,35], the others intervention control studies. Four stud-
ies were performed in an urban environment [21,23,25,27], with the largest study covering an
entire town [25]; the other six [24,28,32,33,34,35] were conducted in villages and rural areas.
In six of the studies [21,23,24,28,32,35], pyriproxyfen had a significant (82–100% EI) and
long lasting (up to 8 months) effect. However, the two RCTs reported less positive results with
significant effects for 4 weeks only. However, it must be considered that one RCT [25] mea-
sured catch basin positivity, making comparison with the other studies difficult. It also had
several additional constraints such as moderate Aedes indices, low pupae/person indices from
the start, inability to reach the intended sample size, and the emergence of a dengue epidemic
during the intervention. The other RCT [35] and one nRCT [34] reported treatment persis-
tence of only 4 weeks, though initial larval densities were significantly reduced.
One study [21] found a variable larvicidal effect in 20 containers and attributed this to larvi-
cide dilution, though none of the other container studies reported efficacy limitations with
increasing container sizes. Notably, Sihuincha [27] treated different sizes of water tanks suc-
cessfully for five months despite a high turnover of the treated water.
Regarding area-wide ULV application, two studies [23,32] recommend this method of
application over a wide range of container sizes, while one [33] found it not suitable for either
larval habitat treatment or auto-dissemination. The two studies that did report good results
with ULV application [23,32] used pyriproxyfen combined with permethrin.
As for persistence in container treatment, slow-release formulations had the best results.
Sihuincha [27] reported a mortality rate >80% over five months with application by gauze
bags, Seng [28] reported similar effects over eight months with resin strands and Seccacini
[24] reported 100% EI at six months using pyriproxifen-impregnated O-rings. A shorter per-
sistence of four weeks was reported from a large field trial with granules in water in Martinique
[35], while the longest duration of effective EI through ULV treatment was 35 days [23], and
the shortest only two weeks [32].
Analysis of fumigation studies
Two studies [21,22] examined the use of fumigant canisters. Both used a combination of pyri-
proxyfen and permethrin and reported a significant inhibitory effect on adult emergence of
Ae. aegypti as well as on BI. However, the size of the effect and persistence (less than 9 weeks)
was limited. Adding outdoor ULV application of permethrin increased the effectiveness of the
intervention.
Pyriproxifen and dengue vector control
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Table 3. Summary of categorised results.
Summary of container treatment studies
Study No Pyriproxyfen Max EI % Main indices Follow up time
Formulation Dose Application




Marcombe 2011 Sumilarv 0.5% GR 0.05 mg/l Granules in water > 95 RD < 20% 4 weeks
Seng 2008 Pyriproxyfen 135 mg w/w
containing 6 mg a.i.
per strand
Resin strands 3
mm x 40 mm
99.8 - 34 weeks
Doud 2014 Nyguard 10% emulsifiable
concentrate
164 ml/ha and 329
ml/ha
ULV spray > 82 - 2 weeks
Lucia 2009 Emulsifiable concentrate
3% (plus permethrin)
2 g/ha (plus 10 g
permethrin)
ULV spray 96 - 35 days
Suman 2014 Nyguard 10% emulsifiable
concentrate
0.86 l/min Point source
treatment and area
wide treatment
- 60.8 in 2010 (38.3 in
2011) % larval
mortality
6 weeks each in 2
consecutive years
Dantur Juri 2013 3% pyriproxyfen plus 10%
permethrin as
100 mL per ha Emulsifiable
concentrate
100 BI 72 3 weeks
Darriet 2010 0.02 mg/l - - Fluctuating RD fluctuating 21 days
Sihuincha 2005 Granular formulation
0.5%
50–83 ppb (= 10
mg/l)










100 - 6 months
Summary of fumigation treatment studies




Dantur Juri 2013 10% permethrin and 2% pyriproxifen fumigant tablet 96 (down from 120) 4
weeks after treatment
8 weeks (9 weeks
when combined with
ULV)
Harburguer 2011 1% permethrin + 0.2% pyriproxifen fumigant tablet 11 2 weeks
Summary of autodissemination studies




Ponlawat 2013 0.5 G 0.05 g a.i./ m2 Only adult counts by BGS trap
provided
13 weeks
Devine 2009 0.5% granular formulation, pulverised 5 g / m2 98 98 12 days
Caputo 2012 5%, grinded to powder 1 g per cloth (12x8
cm)
- 70 12 days
Snetselaar 2014 10% emulsifiable concentrate 798.23 ml/ha - 10.3% in 2010 (2.9%
in 2011)
6 weeks
Suman 2014 Pyriproxyfen by Chemos GmbH - - > 90% 18 days
Summary of combination product studies
Study No Pyriproxyfen Max EI % Main indices Follow up time
Formulation Dose Application
Harburguer 2011 10% permethrin and 2%
pyriproxifen
2 tablets per house
and 380 cubic cm
every 36s
Fumigant tablet - BI 96 after 4 weeks
(down from 120)
8 weeks (9 weeks
when combined with
ULV)
Tsunoda 2013 EcoBio-block S with
0.016% pyriproxyfen (plus
permethrin as Olyset Net)
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Analysis of auto-dissemination studies
Six studies evaluated auto-dissemination. The only RCT examining auto-dissemination [30]
found significant results only in their BGS trap counts. However, these are known to be the
most sensitive when counts are low from the start [39]. The remaining studies [26,33,36,37],
using intervention control designs, primarily demonstrated that this approach is efficacious
and that it can be applied easily and at low costs.
Caputo [36] performed field experiments with wild Ae. albopictus and reported an inhomo-
geneous product transfer to different sentinel sites. However, it was rightly pointed out that if
the approach is applied to reduce Ae. albopictus adult densities, the mosquitoes themselves will
disseminate the larvicide to the most attractive (i.e. most productive) natural breeding sites.
Devine [26] used 0.5% pyriproxyfen concentration in 1 l plastic containers and demon-
strated overall reductions of Ae. aegypti adult emergence of 49–84%, as opposed to 7–8% in
controls. In another experiment [36] with the same pyriproxyfen concentration, the overall
reduction of Ae. albopictus adult emergence was 20.8%, as opposed to 2.4% mortality in con-
trols. Given that the LC50 reported for Ae. albopictus (0,11 ppb; [39]) is about 10 times higher
than that reported for Ae. aegypti, this is a promising result.
Analysis of combination product studies
Seven of the reviewed studies combined pyriproxyfen with interventions targeting adults as
well. They did not stratify the effects by product but rather as combined results. Five studies
evaluated pyriproxyfen in combination with permethrin [21,22,23,29,31], one in combination
with the fungus B. bassiana [35], and one with Spinosad [34].
Two of these studies were RCTs [22,31]. Both found significant changes through their
respective interventions. While both used a combination of pyriproxyfen with permethrin,
their application differed (fumigation versus EcoBio-block S) and so did their measured out-
come values (BI versus CI and seroprevalence studies). Direct comparison is difficult but it can
be summarised that they had good results that lasted for 9 weeks (fumigation plus ULV) and 5
months (EcoBio-block S), respectively. Similar results were reported in the non-RCTs.
In summary, the combination of adulticidal and larvicidal products can increase effective-
ness by simultaneously controlling adults and larvae, and by expanding persistence [22].
Resistance and combination treatments
Only one study found and reported on resistance of pyriproxyfen. Marcombe [35] demon-
strated Ae. aegypti being tolerant against pyriproxyfen presumably due to cross-resistance
with temephos, as pyriproxyfen had never been used on the island of Martinique before.
Table 3. (Continued)
Lucia 2009 Emulsifiable concentrate
3% (plus permethrin)
2 g/ha (plus 10 g
permethrin)
ULV spray 96 - 35 days
Limpawitthayakul
2011
Temephos 1% SG and
Pyriproxifen 0,5% G
- - - Sustainable killing
effect
9/13 weeks
Dantur Juri 2013 Emulsifiable concentrate
3% (plus permethrin)
100 ml/ha ULV spray 100 in 250
ml; 20 in 20 l






- Fluctuating RD 21 days
(pyriproxyfen), 4,5
months (mix)
Snetselaar 2014 Mix of B. bassiana plus
pyriproxyfen
- Dust mix applied on
gauze
- > 90% larval mortality 18 days
https://doi.org/10.1371/journal.pntd.0005651.t003
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Community participation and acceptance
Three of the included studies [22,25,28] described community perceptions and uptake of the
interventions. Seng [26; Cambodia] reported overwhelmingly positive perceptions after an ini-
tial period of concern. Harburguer [22; Argentina] found the community capable and ready to
participate in a mosquito control programme by using non-professional control tools (fumi-
gant tablet). However, the authors also highlight the community’s reluctance to take part in
training workshops, even though most applied the tablet while only 16% attended the work-
shop. The third study ([25]; Colombia) describes the importance of engaging and empowering
local field staff regarding design and operation of entomological surveillance activities.
Discussion
This systematic review of the CE of the juvenile hormone mimic pyriproxyfen against Aedes
spp. presents evidence suggesting that pyriproxyfen can effectively control the adult emergence
of immature stages of dengue vector mosquitoes in a variety of real world habitats. If the most
productive breeding sites are identifiable and accessible–e.g. catch basins, water storage con-
tainers—direct treatment by monthly application appears to be the most effective and feasible
with controlled-release formulations having strong and long-lasting effects.
With regards to efficacy, inconsistent results were presented [11,27]. These are most proba-
bly the result of differences between strains, formulations, and experimental conditions. There
is a clear evidence that pyriproxyfen effectively inhibits Aedes adult emergence at concentra-
tions of<1 ppb.
As to the methods of application, the evidence is highly variable. For container treatment,
the effectiveness of pyriproxyfen seems to depend on factors such as the material of which the
individual containers are made and the local environmental conditions. For example, Vythilin-
gam [40] reported much higher levels of sustained residual activity in plastic tubs than in
earthen jars, while Schaefer [41] and Glare [42] demonstrated a lower stability of pyriproxyfen
at higher temperatures. In addition, there seems to be a natural inter-individual variation
between containers [35]. There are contradictory reports on whether different container sizes
play a relevant role, probably to be addressed by the amount of pyriproxyfen used.
Overall, the available evidence shows that a targeted treatment with a slow-release (e.g.
granular) or a long-lasting (e.g. resin strands) formulation can yield an adequate EI for up to
34 weeks. However, more research is needed to define the lowest effective concentrations for
each formulation and the frequency by which the treated containers should be replenished.
Studies should be performed with standard containers in field trials to avoid accurate estimates
of mosquito density being obscured by random variation among individual containers. Also,
further work is needed to determine the impact of environmental conditions (UV light, dilu-
tion, temperature, etc.) on effectiveness and persistence.
Regarding ULV application, only interventions with a product combination (e.g. permeth-
rin) showed a significant effect, suggesting that ULV treatment with pyriproxyfen alone cannot
be recommended. Some authors discussed the potential reasons for the failure of ULV and
hypothesised that a) container openings were too small for pyriproxyfen to enter; b) treatment
surfaces were too small to cover a significant number of breeding sites; c) extreme weather
conditions (first year very dry, second year higher than usual precipitation) adversely impacted
the larvicidal effect; d) cryptic habitats of Ae. albopictus not accessed or e) the slow mode of
action of pyriproxifen was not considered in the follow up evaluation [32, 33].
Space spraying–here as fumigation—has shown its effect only indoors, and it should be
considered as part of a multi-intervention approach.
Pyriproxifen and dengue vector control
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According to Devine [26], auto-dissemination could be an interesting approach to reach
elusive breeding sites. Sihunicha [27] showed that an exposure of 30 min to water containing
0.003 g a.i./m2 pyriproxyfen allowed for horizontal transfer of effective larvicidal pyriproxyfen
doses to untreated environments. The same study reports that subsequent eclosion of eggs was
decreased by 70–90%.
Different ovitraps have been designed and their effectiveness tested. Extraordinarily low
doses of pyriproxifen (Ae. aegypti: LC50 = 0.011 ppb (11), 0.012 [27], 0.0039 ppb [43]; Ae. albo-
pictus: LC50 = 0.11 ppb [45]) are needed for this approach [27,44]. The herein reviewed studies
reported maximum distances of 150 m (28 2013) and 200 m [45] travelled by the mosquito
from the treatment sites. These are in line with Marini et al. [46] who demonstrated that gravid
female Aedes spp. travel 50–200 m from the release sites. Kaufmann et al. [47] reported longer
distances of up to 3 km. Further studies are needed to prove and improve the auto-dissemina-
tion strategy under field conditions. Specifically, methods of application, concentrations and
frequencies of treatment need to be clarified.
Controlled-release/long-lasting formulations had a good effect with much longer persis-
tence than other treatments. In order to improve adherence in community based approaches,
such interventions should be preferred. They may even be more efficient as re-treatment
would have to be less often and, therefore, the overall operation is more cost-effective as less
professional personnel is involved.
Those studies that combined the application of pyriproxyfen with different adulticidal
products clearly showed that effectiveness can be increased by simultaneously controlling
adults and larvae, and by expanding persistence [22].
From the presented studies, there is insufficient evidence to determine what impact the
level of motivation in a community could have on vector control. This question warrants fur-
ther investigation in larger prospective studies. Such trials are also needed to assess whether
and how communities can be motivated and control efforts sustained.
The majority of the included studies were from South and Central America, yet, Bhatt [1]
postulates that Africa’s dengue burden is nearly equivalent to that of the Americas (i.e. 16 (11–
22) million infections annually, representing, 16% of the global total). Also, India is estimated
to contribute 34% (i.e. 33 (24–44) million infections per year) of the global total dengue infec-
tions. Further evidence is required on the effectiveness of pyriproxyfen in Africa and India to
understand the influence of local environmental and societal factors.
Concluding, although pyriproxyfen is highly effective in killing the larvae of dengue trans-
mitting vectors, and–to a smaller degree–also adult mosquito stages, evidence for the reduc-
tion of human disease transmission is weak. Lack of evidence is primarily due to small
sample sizes, inappropriate study designs and lack of relevant, standardised outcome mea-
sures. Before issuing specific recommendations for the routine use of pyriproxyfen as a larvi-
cide in dengue control programmes these research gaps must be addressed. Additionally,
cross-resistance to pyriproxyfen has previously been reported by Macoris-Andrighetti [48]
and, should it be verified, would have operational consequences for future dengue vector
control. It therefore requires further attention in future studies as well as public health
programmes.
Supporting information
S1 Checklist. PRISMA checklist for “Community effectiveness of Pyriproxyfen as a Den-
gue Vector Control Method: A Systematic Review”.
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